Download PDF
Klin Monbl Augenheilkd 2010; 227(2): R15-R28
DOI: 10.1055/s-0029-1240867
KliMo-Refresher
Rubrikherausgeber: G. Duncker, Halle
© Georg Thieme Verlag KG Stuttgart · New York

Neovaskularisationsglaukom

R. A. Widder1 , K.-D. Lemmen1 , T. S. Dietlein2
  • 1Augenklinik des St. Martinus-Krankenhauses, Düsseldorf
  • 2Zentrum für Augenheilkunde der Universität zu Köln
Further Information

Publication History

Publication Date:
12 February 2010 (online)

Also available at
    Permissions and Reprints

Einleitung

Neovaskularisationsglaukome sind eine große Herausforderung. Sie treten meist im Spätstadium einer Vielzahl von Gefäßerkrankungen der Netzhaut auf, die als gemeinsame Endstrecke eine ischämisch-proliferative Retinopathie entwickelt haben. Ihre Prognose ist ernst, immerhin erfolgen 12–15 Prozent aller Enukleationen wegen eines neovaskulären Glaukoms [4].

Entsprechend vielfältig sind die Anforderungen an eine effektive Behandlung, die ein optimiertes Patientenmanagement an der Schnittstelle zwischen Glaukomatologie und Retinologie erfordert:

Wie können derartige Verläufe frühzeitig erkannt und ihre Komplikationen vermieden werden? Welche drucksenkenden Konzepte (medikamentöse Glaukomtherapie, zyklodestruktive Glaukomchirurgie, filtrierende Glaukomchirurgie, Drainage-Implantate) sind bei diesen speziellen Patienten anwendbar? Welche retinologischen Behandlungskonzepte (panretinale Laserkoagulation, intravitreale oder intrakamerale Injektionen, Pars-plana-Vitrektomie) müssen primär durchgeführt oder parallel eingeleitet werden?

Literatur

  • 1 The Diabetic Retinopathy Study Research Group . Indications for photocoagulation treatment of diabetic retinopathy.  Int Ophthalmol Clin. 1987;  27 239-253
    CrossrefPubMedGoogle Scholar
  • 2 The Central Vein Occlusion Study Group . Natural history and clinical management of central retinal vein occlusion.  Arch Ophthalmol. 1997;  115 486-491
    PubMedGoogle Scholar
  • 3 Macugen Retinopathy Diabetic Study Group . Changes in retinal neovascularisation after pegaptanib (macugen) therapy in diabetic individuals.  Ophthalmology. 2006;  113 23-28
    CrossrefPubMedGoogle Scholar
  • 4 Agostini H J, Funk J. Neovaskuläres Glaukom. Schlote TRJ Sekundärglaukome. Stuttgart; Schattauer 2004: 237-248
    PubMedGoogle Scholar
  • 5 Aiello L P, Avery R L, Arrigg P G et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
    CrossrefPubMedGoogle Scholar
  • 6 Arevalo J F, Wu L, Sanchez J G et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.  Eye. 2009;  23 117-123
    CrossrefPubMedGoogle Scholar
  • 7 Brown G C, Magargal L E, Schachat A et al. Neovascular glaucoma. Etiologic considerations.  Ophthalmology. 1984;  91 315-320
    PubMedGoogle Scholar
  • 8 Brown G C, Shah H G, Magargal L E et al. Central retinal vein obstruction and carotid artery disease.  Ophthalmology. 1984;  91 1627-1633
    PubMedGoogle Scholar
  • 9 Brown G C, Brown M M. The ocular ischemic syndrome. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 519-527
    PubMedGoogle Scholar
  • 10 Browning D J, Scott A Q, Peterson C B et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion.  Ophthalmology. 1998;  105 776-784
    CrossrefPubMedGoogle Scholar
  • 11 Burton M G Z. Retinal artery occlusion. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 507-518
    PubMedGoogle Scholar
  • 12 Caprioli J, Strang S L, Spaeth G L et al. Cyclocryotherapy in the treatment of advanced glaucoma.  Ophthalmology. 1985;  92 947-954
    PubMedGoogle Scholar
  • 13 Dietlein T S, Hermann M M, Jordan J F. The medical and surgical treatment of glaucoma.  Dtsch Arztebl Int. 2009;  106 597-605 quiz 606
    PubMedGoogle Scholar
  • 14 Eid T E, Katz L J, Spaeth G L et al. Tube-shunt surgery versus neodymium:YAG cyclophotocoagulation in the management of neovascular glaucoma.  Ophthalmology. 1997;  104 1692-1700
    PubMedGoogle Scholar
  • 15 Eid T M, Radwan A, el-Manawy W et al. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.  Can J Ophthalmol. 2009;  44 451-456
    CrossrefPubMedGoogle Scholar
  • 16 Fakhraie G, Katz L, Prasad A et al. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.  Journal of Glaucoma. 2009;  , Epub ahead of print
    PubMedGoogle Scholar
  • 17 Falavarjani K, Modarres M, Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.  Eye. 2009;  , Epub ahead of print
    PubMedGoogle Scholar
  • 18 Grisanti S, Biester S, Peters S et al. Intracameral bevacizumab for iris rubeosis.  Am J Ophthalmol. 2006;  142 158-160
    CrossrefPubMedGoogle Scholar
  • 19 Grover S, Gupta S, Sharma R et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.  Br J Ophthalmol. 2009;  93 273-274
    CrossrefPubMedGoogle Scholar
  • 20 Iliev M E, Domig D, Wolf-Schnurrbursch U et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.  Am J Ophthalmol. 2006;  142 1054-1056
    CrossrefPubMedGoogle Scholar
  • 21 Joussen A M, Adamis A P. Inflammation as a stimulus for vascular leakage and proliferation. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 97-107
    PubMedGoogle Scholar
  • 22 Katz G J, Higginbotham E J, Lichter P R et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up.  Ophthalmology. 1995;  102 1263-1269
    PubMedGoogle Scholar
  • 23 Lang G E. Laser treatment of diabetic retinopathy.  Dev Ophthalmol. 2007;  39 48-68
    PubMedGoogle Scholar
  • 24 Lim T H, Bae S H, Cho Y J et al. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma.  Korean J Ophthalmol. 2009;  23 188-192
    CrossrefPubMedGoogle Scholar
  • 25 Lin S C. Endoscopic and transscleral cyclophotocoagulation for the treatment of refractory glaucoma.  J Glaucoma. 2008;  17 238-247
    CrossrefPubMedGoogle Scholar
  • 26 Madsen P H. Haemorrhagic glaucoma. Comparative study in diabetic and nondiabetic patients.  Br J Ophthalmol. 1971;  55 444-450
    CrossrefPubMedGoogle Scholar
  • 27 Mason J O, Albert M A, Mays A et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.  Retina. 2006;  26 839-841
    CrossrefPubMedGoogle Scholar
  • 28 Matsuyama K, Ogata N, Jo N et al. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.  Jpn J Ophthalmol. 2009;  53 243-248
    CrossrefPubMedGoogle Scholar
  • 29 Mermoud A, Salmon J F, Alexander P et al. Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome.  Ophthalmology. 1993;  100 897-902
    PubMedGoogle Scholar
  • 30 Mizener J B, Podhajsky P, Hayreh S S. Ocular ischemic syndrome.  Ophthalmology. 1997;  104 859-864
    PubMedGoogle Scholar
  • 31 Molteno A C, Haddad P J. The visual outcome in cases of neovascular glaucoma.  Aust N Z J Ophthalmol. 1985;  13 329-335
    CrossrefPubMedGoogle Scholar
  • 32 Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularisation.  Graefes Arch Clin Exp Ophthalmol. 1994;  232 199-204
    CrossrefPubMedGoogle Scholar
  • 33 Ohrt V. The frequency of rubeosis iridis in diabetic patients.  Acta Ophthalmol (Copenh). 1971;  49 301-307
    PubMedGoogle Scholar
  • 34 Oshima Y, Sakaguchi H, Gomi F et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.  Am J Ophthalmol. 2006;  142 155-158
    CrossrefPubMedGoogle Scholar
  • 35 Rüfer F, Roider J. General concepts in laser treatment for retinal vascular disease. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 3309-3341
    PubMedGoogle Scholar
  • 36 Saito Y, Higashide T, Takeda H et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.  Acta Ophthalmol. 2009;  , Epub ahead of print
    PubMedGoogle Scholar
  • 37 Schlote T, Bartz-Schmidt K U. Treatment of rubeotic secondary glaucoma. Joussen AM, Gardner T, Kirchhof B, Ryan SJ Retinal vascular disease. Heidelberg; Springer 2007: 274-282
    PubMedGoogle Scholar
  • 38 Scott I U, Alexandrakis G, Flynn H W et al. Combined pars plana vitrectomy and glaucoma drainage implant placement for refractory glaucoma.  Am J Ophthalmol. 2000;  129 334-341
    CrossrefPubMedGoogle Scholar
  • 39 Shields M B, Shields S E. Noncontact transscleral Nd:YAG cyclophotocoagulation: a long-term follow-up of 500 patients.  Trans Am Ophthalmol Soc. 1994;  92 271-287
    PubMedGoogle Scholar
  • 40 Shin J P, Lee J W, Sohn B J, Kim H K et al. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with ahmed valve implantation.  J Glaucoma. 2009;  18 589-594
    CrossrefPubMedGoogle Scholar
  • 41 Sidoti P A, Dunphy T R, Baerveldt G et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma.  Ophthalmology. 1995;  102 1107-1118
    PubMedGoogle Scholar
  • 42 Sivak-Callcott J A, O'Day D M, Gass J D et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.  Ophthalmology. 2001;  108 1767-1776 quiz 1777 1800
    CrossrefPubMedGoogle Scholar
  • 43 Takihara Y, Inatani M, Fukushima M et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.  Am J Ophthalmol. 2009;  147 912-918
    CrossrefPubMedGoogle Scholar
  • 44 Tsai J C, Feuer W J, Parrish R K et al. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study.  Ophthalmology. 1995;  102 887-893
    PubMedGoogle Scholar
  • 45 Tsai J C, Wand M. Neovascular glaucoma. Albert AM, Miller J Principles and practice of ophthalmology. Philadelphia; Elsevier 2008: 2689-2712
    PubMedGoogle Scholar
  • 46 Uram M. Ophthalmic laser microendoscope ciliary process ablation in the management of neovascular glaucoma.  Ophthalmologie. 1992;  99 1823-1828
    PubMedGoogle Scholar
  • 47 Vasudev D, Blair M P, Galasso J et al. Intravitreal bevacizumab for neovascular glaucoma.  J Ocul Pharmacol Ther. 2009;  25 453-458
    CrossrefPubMedGoogle Scholar
  • 48 Wakabayashi T, Oshima Y, Sakaguchi H et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.  Ophthalmologie. 2008;  115 1571-1580
    CrossrefPubMedGoogle Scholar
  • 49 Yazdani S, Hendi K, Pakravan M et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.  J Glaucoma. 2009;  18 632-637
    CrossrefPubMedGoogle Scholar
  • 50 Yildirim N, Yalvac I S, Sahin A et al. A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma: a long-term follow-up.  J Glaucoma. 2009;  18 192-196
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. med. Randolf A. Widder

Augenklinik St. Martinus-Krankenhaus

Gladbacher Straße 26

40219 Düsseldorf

Email: r.widder@martinus-duesseldorf.de